- Hepatitis B treatments and diagnostics are increasingly vital components of Europe’s public health infrastructure, especially in both hospital and outpatient settings, due to rising infection awareness, improved testing accessibility, and advancements in antiviral therapies
- The escalating demand for effective Hepatitis B management is primarily fueled by government vaccination programs, an increase in HBV-HDV co-infection screening, and the growing burden of chronic liver diseases among aging populations
- Germany dominated the Europe hepatitis B infection market with the largest revenue share of 34.7% in 2024, characterized by strong public health policies, early adoption of advanced diagnostic tools, and high HBV testing rates. The country has also seen significant growth in treatment uptake, particularly among high-risk groups and immigrants, driven by awareness campaigns and improved reimbursement frameworks
- U.K. is expected to be the fastest growing region in the Europe Hepatitis B Infection market, driven by the integration of HBV testing into primary care settings and strong national immunization strategies. The NHS’s emphasis on adult and childhood immunization programs remains a key contributor to market expansion
- The chronic segment dominated the Europe Hepatitis B Infection market with a market share of 62.4% in 2024, driven by its persistent nature, the need for long-term monitoring and therapy, and rising detection rates from enhanced screening initiatives
